Navigation Links
Bionovo Announces 2010 Highlights and Year-End Financial Results
Date:3/15/2011

and metabolic syndrome.
  • In July, Bionovo entered into a $15 million, at-the-market firm commitment financing agreement with Aspire Capital. Although the Company has not yet accessed this facility, it is still available under the original conditions. Further, Aspire Capital participated in the underwritten offering that closed in February, 2011.
  • The Company also announced additions to its network of advisors and consultants, including leading healthcare professionals with extensive experience in the development of therapeutic treatments:
  • Dr. Richard Weiner, PhD, Emeritus Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences, at the University of California, San Francisco.
  • Dr. Paul Pui-Hay But, PhD, Chief Scientist for the Food and Drug Authentication Laboratory Ltd., Hong Kong, China.

  • Full Year ResultsFor the year ended December 31, 2010 total revenues were $0.6 million compared with $0.3 million for the same period in 2009. Revenues in 2010 consisted of a Qualifying Therapeutic Discovery Project Credit of $0.5 million and $0.1 million in a National Institute of Health (NIH) grant drawdown.  Revenue in 2009 was comprised of approximately $55,000 in limited research services revenue combined with $0.2 million in NIH grant drawdown.

    For the year ended December 31, 2010 total operating expenses were $18.2 million compared with $16.6 million for the same period in 2009. The increase in 2010 operating expenses were primarily due to additional expenses to support our Menerba manufacturing process development.

    The net loss for the year ended December 31, 2010 was $17.7 million, or $0.80 per share, compared with a net loss of $16.4 million, or $0.98 per share, for the same period in 2009. The year-over-year increase in net loss was driven primarily by the expenses related to the Menerba manufacturing process development and 2010 director and employee performance bonuse
    '/>"/>

    SOURCE Bionovo, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Bionovo, Inc. to Announce Fourth Quarter Fiscal Year 2010 Financial Results on Tuesday, March 15, 2011
    2. Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference
    3. Bionovo Announces 2011 Plan of Action on MF101 (Menerba™)
    4. Bionovo Announces Pricing of Follow-on Offering of Common Stock and Warrants
    5. Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors
    6. Bionovo Releases FDA-Approved Clinical Development Plan for Menerba
    7. Bionovo Announces Publication Describing Estrogen Receptor Beta Cancer Prevention Mechanism
    8. Bionovo Announces Third Quarter 2010 Highlights and Financial Results
    9. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2010 Financial Results on Thursday, November 11, 2010
    10. Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions
    11. Bionovo to Raise $3 Million Through Registered Direct Offering
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/17/2015)... , April 17, 2015  Healthcare reform ... of many new forms of provider networks, such ... Organizations (ACOs). The rapid evolution of these networks ... their access, pricing and service delivery systems to ... To help the pharma sector adapt to ...
    (Date:4/17/2015)... 2015 Research and Markets ( ... "Medical Device Outsourcing - Global Strategic Business ... This report analyzes the worldwide markets for Medical ... Device Categories: Class I, Class II, and Class ... report Include - Radiology, Orthopedic, Neurology, Cardiology, and ...
    (Date:4/17/2015)... 17, 2015  Trovagene, Inc., (NASDAQ:  TROV) a ... clinical data presented at the 2015 European Lung ... Cancer Monitoring ℠ (PCM) platform outperformed tissue ... EGFR T790M mutations in metastatic lung cancer ... T790M Mutation in Urinary Circulating Tumor DNA from ...
    Breaking Medicine Technology:Pharmaceutical Industry Struggling to Better Serve Provider Networks Such as Accountable Care Organizations (ACOs) 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4
    ... BETHESDA, Md., April 14 Micromet, Inc.,(Nasdaq: ... novel, proprietary,antibodies for the treatment of cancer, ... meeting of the American Association for,Cancer Research ... that commercial,anti-cancer antibodies trastuzumab (Herceptin(R); Genentech, Roche),cetuximab ...
    ... the, Tumor Suppressor P53 Inhibited Tumor Growth Synergistically in Preclinical ... ... 14 ,Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) announced today that ... 2008 Annual Meeting of the American Association for Cancer Research,(AACR) further ...
    Cached Medicine Technology:Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 2Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 3Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 4Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 5Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 2Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 3Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 4
    (Date:4/18/2015)... Compare-autoinsurance.org has released a new blog ... insurance policy . , Clients should no longer ... online is safe and reliable. An insurance brokerage website ... displayed on a single web page, so drivers do ... is now possible to compare online car insurance quotes ...
    (Date:4/18/2015)... April 18, 2015 "I wanted ... to create a healthful juice that contained essential ... Rosedale, Md. "It increases my energy, improves skin ... , He developed Tapp's Juice to contain fruits, ... to prevent physical and mental fatigue. It features ...
    (Date:4/18/2015)... Patients who undergo radiation for a hematologic cancer ... but the disease is likely to differ in some ... Surviving Mesothelioma has just posted the details of this ... read it now. , Scientists from China, the ... who had both a hematologic cancer (like lymphoma or ...
    (Date:4/18/2015)... 18, 2015 Aureus Medical Group ... including physical therapy jobs, has announced that it ... Carolina Physical Therapy Association Annual Conference to be ... in Greenville, SC. , The SCAPTA Annual ... with products and services. , Representatives from ...
    (Date:4/17/2015)... John Evans, a Gardant affordable assisted ... from 2 p.m. to 3 p.m. on April 24. ... Ct. in Pekin, Illinois, serves older adults of all ... to maintain their independence. , Becky Baker will entertain ... be served during the luau. , For more information, ...
    Breaking Medicine News(10 mins):Health News:A Guide For Avoiding Online Auto Insurance Scams! 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2
    ... July 8 Governor Edward G.,Rendell today issued ... Containment Council (PHC4), which closed after the law,authorizing ... Governor acted similarly in 2003, when PHC4 was ... later reauthorized by legislative action., The Rendell ...
    ... Study Validates Use of Pharos Innovation,s Proprietary,Device-Free Remote Monitoring Platform ... ... Medical Costs, NORTHFIELD, Ill., July 8 ... generation clinical and financial,performance improvement through a device-free remote monitoring ...
    ... Barbara Ann Karmanos,Cancer Center announced that it has ... lease space and equipment at the Meadowbrook Medical,Center, ... foot,space will allow Karmanos to expand its outreach ... as well as provide access to radiation,oncology, medical ...
    ... single nucleotide polymorphisms (SNPs), that are associated with a ... breast cancer do not appear to substantially improve the ... predict an individual,s risk, according to a study in ... of the National Cancer Institute . , Risk prediction ...
    ... PITTSBURGHUniversity of Pittsburgh-led researchers could provide new insight ... deformity and arteriovenous malformations (AVMs)develop in humans, as ... Developmental Biology . , Led by Beth Roman, ... School of Arts and Sciences, the team created ...
    ... yet to show drop-off in access predicted by critics ... have not lost access to care despite federal legislation ... years, a new report finds. , Critics feared the ... make treatment more difficult, but investigators from the Duke ...
    Cached Medicine News:Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 2Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 3Health News:Iowa Medicaid Demonstration Finds Tel-Assurance(R) Remote Monitoring Platform Improved Health Status and Saved $5 Million 2Health News:Iowa Medicaid Demonstration Finds Tel-Assurance(R) Remote Monitoring Platform Improved Health Status and Saved $5 Million 3Health News:Karmanos Cancer Center Partners With Meadowbrook to Expand Outreach and Access for Cancer Services 2Health News:Single-nucleotide polymorphisms do not substantially improve risk prediction for breast cancer 2Health News:Pitt-led research provides insight into development of congenital circulatory defects 2Health News:Cancer Care Unaffected by Doctor Reimbursement Changes 2
    The rotating stage assembly is designed to give the researcher maximum flexibility in the mounting of specimens. It can be turned to any horizontal and vertical angle via a ball joint mounting arran...
    Punch set for Advanced Tissue Arrayer, 2.0 mm...
    Inquire...
    Inquire...
    Medicine Products: